Our study has demonstrated the potential role of inhibition of TGFβ1 signaling via TGFβR2 for improved survival, reduced inflammation and apoptosis that may provide insights for the development of novel therapeutic strategies targeted against HALI and BPD. This evidence concerns the gene TGFB1 and bronchopulmonary dysplasia.